Stahler A, Modest DP, Fischer von Weikersthal L, Kaiser F, et al. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAV Eur J Cancer 2022;173:194-203.
PMID: 35940054